摘要：

Disclosed is a pharmaceutical composition comprising orlistat and a plant-derived lipase inhibitor. The plant-derived lipase inhibitor is a polyphenol lipase inhibitor extracted from tea. The results of tests in vitro show that when the molar ratio of orlistat and the polyphenol lipase inhibitor is in the range of 1:10-10:1, the interaction index of inhibiting lipase activity is lower than 1, indicating that the two have a synergistic lipase inhibitory effect. The results of animal testing show that the effect of the composition comprising orlistat and the polyphenol lipase inhibitor on controlling the weight of rats with nutritional obesity is better than that of the group including the independent administration of an orlistat group and the polyphenol lipase inhibitor, further verifying the production of a synergistic effect. In addition, the polyphenol lipase inhibitor can reduce the unpleasant gastrointestinal side effects of orlistat, and alleviate oil spots, fatty/greasy stools and other adverse reactions.

展开